Abstract
Angiogenesis is essential for tumour growth beyond 1 to 2 mm in diameter. The clinical relevance of angiogenesis, as assessed by microvessel density (MVD), is unclear in malignant mesothelioma (MM). Immunohistochemistry was performed on 104 archival, paraffin-embedded, surgically resected MM samples with an anti-CD34 monoclonal antibody, using the Streptavidin–biotin complex immunoperoxidase technique. 93 cases were suitable for microvessel quantification. MVD was obtained from 3 intratumoural hotspots, using a Chalkley eyepiece graticule at × 250 power. MVD was correlated with survival by Kaplan–Meier and log-rank analysis. A stepwise, multivariate Cox model was used to compare MVD with known prognostic factors and the EORTC and CALGB prognostic scoring systems. Overall median survival from the date of diagnosis was 5.0 months. Increasing MVD was a poor prognostic factor in univariate analysis (P = 0.02). Independent indicators of poor prognosis in multivariate analysis were non-epithelial cell type (P = 0.002), performance status > 0 (P = 0.003) and increasing MVD (P = 0.01). In multivariate Cox analysis, MVD contributed independently to the EORTC (P = 0.006), but not to the CALGB (P = 0.1), prognostic groups. Angiogenesis, as assessed by MVD, is a poor prognostic factor in MM, independent of other clinicopathological variables and the EORTC prognostic scoring system. Further work is required to assess the prognostic importance of angiogenic regulatory factors in this disease. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Antony VB, Hott JW, Godbey SW and Holm K (1996) Angiogenesis in mesotheliomas. Role of mesothelial cell derived IL-8. Chest 109: 21S–22S
Attanoos RL, Suvarna SK, Rhead E, Stephens M, Locke TJ, Sheppard MN, Pooley FD and Gibbs AR (2000) Malignant vascular tumours of the pleura in “asbestos” workers and endothelial differentiation in malignant mesothelioma. Thorax 55: 860–863
Banks R, Forbes M, Kinsey S, Stanley A, Ingham E, Walters C and Selby P (1998) Release of angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Brit J Cancer 77: 956–964
Bicknell R and Harris AL (1996) Mechanisms and therapeutic implications of angiogenesis. Current Opinions in Oncology 8: 60–65
Calabrese L and Fleischer AB (2000) Thalidomide: current and potential clinical applications. Am J Med 108: 487–495
Chaudhary R, Bromley M, Clarke NW, Betts CD, Barnard RJ, Ryder WD and Kumar S (1999) Prognostic relevance of micro-vessel density in cancer of the urinary bladder. Anticancer Res 19: 3479–3484
Cherrington JM, Strawn LM and Shawver LK (2000) New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res 79: 1–38
Cox D (1972) Regression models and life tables. Journal of the Royal Statistical Society (B) 34: 187–220
Cox G, Jones JL, Andi A, Waller DA and O' Byrne KJ (2001) A biological staging model for operable non-small cell lung cancer. Thorax 56: 561–566
Cox G, Jones JL and O'Byrne KJ (2000a) Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 6: 2349–2355
Cox G, Walker RA, Andi A, Steward WP and O'Byrne KJ (2000b) Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer 29: 169–177
Curran D, Sahmoud T, Therasse P, Van Meerbeeck J, Postmus PE and Giaccone G (1998) Prognostic factors in patients with pleural mesothelioma: The European Organisation for Research and Treatment of Cancer Experience. Journal of Clinical Oncology 16: 145–152
Dickinson AJ, Fox SB, Persad RA, Hollyer J, Sibley GN and Harris AL (1994) Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas. Br J Urol 74: 762–766
Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G, Shimamura H, Shibuya K, Takeda K and Matsuno S (2000) Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res 60: 1111–1116
Eatock MM, Schatzlein A and Kaye SB (2000) Tumour vasculature as a target for anticancer therapy. Cancer Treat Rev 26: 191–204
Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA and O'Byrne KJ (2000) Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55: 731–735
Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC and Harris AL (1995) Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. Journal of Pathology 177: 275–283
Gervaz P and Fontolliet C (1998) Therapeutic potential of the anti-angiogenesis drug TNP-470. Int J Exp Pathol 79: 359–362
Giatromanolaki A, Koukourakis M, O'Byrne K, Fox S, Whitehouse R, Talbot DC, Harris AL and Gatter KC (1996) Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 179: 80–88
Gupta SK, Hassel T and Pal Singh J (1995) A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4. Proc Nat Acad Sci USA 92: 7799–7803
Hanahan D and Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364
Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W and Rose C (2000) The prognostic value of angiogenesis by Chalkley counting in a confirmatory study design on 836 breast cancer patients. Clin Cancer Res 6: 139–146
Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y and Vogelzang NJ (1998) Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113: 723–731
Kumar-Singh S, Vermeulen PB, Weyler J, Segers K, Weyn B, Van Daele A, Dirix LY, Van Oosterom AT and Van Marck E (1997) Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 182: 211–216
Kumar-Singh S, Jacobs W, Dhaene K, Weyn B, Bogers J, Weyler J and Van Marck E (1998) Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 186: 300–305
Kumar-Singh S, Weyler J, Martin KJ, Vermeulen PB and Van Marck E (1999) Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression. J Pathol 189: 72–78
Law M, Gregor A, Hodson ME, Bloom H and Turner-Warwick M (1984) Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax 39: 255–259
Macaulay V, O'Byrne K, Saunders M, Braybrooke J, Long L, Gleeson F, Mason C, Harris A, Brown P and Talbot D (1999) Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 5: 513–520
Martin L, Green B, Renshaw C, Lowe D, Rudland P, Leinster S and Winstanley J (1997a) Examining the technique of angiogenesis assessment in invasive breast cancer. Brit J Cancer 76: 1046–1054
Martin L, Holcombe C, Green B, Leinster S and Winstanley J (1997b) Is a histological section representative of whole tumour vascularity in breast cancer?. Brit J Cancer 76: 40–43
McLean AN and Patel KR (1997) Clinical features and epidemiology of malignant pleural mesothelioma in west Glasgow 1987–1992. Scot Med J 42: 37–39
Motro B, Itin A, Sachs L and Keshet E (1990) Pattern of Interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 87: 3092–3096
Nakano T, Chahinian A, Shinjo M, Tonomura A, Miyake M, Togawa N, Ninomiya K and Higashino K (1998) Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Brit J Cancer 77: 907–912
O'Byrne K, Dobbs N, Propper D, Smith K and Harris A (1999) Vascular endothelial growth factor, platelet counts, and prognosis in renal cancer. Lancet 353: 1494–1495
O'Byrne KJ, Dalgleish AG, Browning MJ, Steward WP and Harris AL (2000) The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Euro J Cancer 36: 151–169
Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M, Watanabe Y and Pass HI (1999) VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Brit J Cancer 81: 54–61
O'Reilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses M, Lane W, Cao Y, Sage E and Folkman J (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315–328
O'Reilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W, Flynn E, Birkhead J, Olsen B and Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277–285
Peto J, Decarli A, La Vecchia C, Levi F and Negri E (1999) The European mesothelioma epidemic. Brit J Cancer 79: 666–672
Pinedo H, Verheul H, D'Amato R and Folkman J (1998) Involvement of platelets in tumour angiogenesis?. Lancet 352: 1775–1777
Procopio A, Strizzi L, Vianale G, Betta P, Puntoni R, Fontana V, Tassi G, Gareri F and Mutti L (2000) Simian virus-40 sequences are a negative prognostic cofactor in patients with malignant pleural mesothelioma. Genes Chromosomes Cancer 29: 173–179
Rusch V (1995) A Proposed New International TNM Staging System for Malignant Pleural Mesothelioma. Chest 108: 1122–1128
Schouwink H, Korse CM, Bonfrer JM, Hart AA and Baas P (1999) Prognostic value of the serum tumour markers Cyfra 21–1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer 25: 25–32
Scott HR, McMillan DC, Crilly A, McArdle CS and Milroy R (1996) The relationship between weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer 73: 1560–1562
Shetty S, Kumar A, Johnson A, Pueblitz S and Idell S (1995) Urokinase receptor in human malignant mesothelioma cells: role in tumor cell mitogenesis and proteolysis. Am J Physiology 268: L972–L982
Sterman DH, Kaiser LR and Albelda SM (1999) Advances in the treatment of malignant pleural mesothelioma. Chest 116: 504–520
Steward W (1999) Marimastat (BB2516): Current status of development. Cancer Chemotherapy and Pharmocology 43, supplS56–S60
Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, DeCamp MM Jr, Swanson SJ, Bueno R, Lukanich JM, Baldini EH and Mentzer SJ (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovas Surg 117: 54–63, discussion 63–65
Talks KL and Harris AL (2000) Current status of antiangiogenic factors. Br J Haematol 109: 477–489
Tolnay E, Kuhnen C, Wiethege T, Konig JE, Voss B and Muller KM (1998) Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma. J Cancer Res Clin Oncol 124: 291–296
Twardowski P and Gradishar W (1997) Clinical trials of antiangiogenic agents. Curr Opin Oncol 9: 584–589
Verheul HM, Hoekman K, Lupu F, Broxterman HJ, van der Valk P, Kakkar AK and Pinedo HM (2000) Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 6: 166–171
Vermeulen P, Gasparini G, Fox S, Toi M, McCulloch P, Pezzella F, Viale G, Weidner N, Harris A and Dirix L (1996) Quantification of Angiogenesis in Solid Human Tumours: an International Consensus on the Methodology and Criteria of Evaluation. Euro J Cancer 32A: 2474–2484
Vermeulen P, Salven P, Benoy I, Gasparini G and Dirix L (1999) Blood platelets and serum VEGF in cancer patients. Br J Cancer 79: 370–376
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Edwards, J., Cox, G., Andi, A. et al. Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 85, 863–868 (2001). https://doi.org/10.1054/bjoc.2001.1997
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1997
Keywords
This article is cited by
-
High-Risk Peritoneal Mesothelioma: Does Metronomic Chemotherapy Have a Role?
Indian Journal of Surgical Oncology (2023)
-
Targeting regulation of VEGF by BPTF in non-small cell lung cancer and its potential clinical significance
European Journal of Medical Research (2022)
-
Microvascular fractal dimension predicts prognosis and response to chemotherapy in glioblastoma: an automatic image analysis study
Laboratory Investigation (2018)
-
Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells
Oncogene (2017)
-
Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples – a short report
Cellular Oncology (2017)